Transgene SA (LON:0OCQ)
0.8400
-0.0040 (-0.47%)
Feb 12, 2026, 8:24 AM GMT
Transgene Employees
Transgene had 147 employees as of June 30, 2025. The number of employees increased by 3 or 2.08% since the number was reported on December 31, 2024.
Employees
147
Change
3
Growth
2.08%
Revenue / Employee
44.17K GBP
Profits / Employee
-214.48K GBP
Market Cap
200.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 147 | 3 | 2.08% |
| Dec 31, 2024 | 144 | 3 | 2.13% |
| Dec 31, 2023 | 141 | -5 | -3.42% |
| Dec 31, 2022 | 146 | 3 | 2.10% |
| Dec 31, 2021 | 143 | 4 | 2.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,000 |
| Integrated Diagnostics Holdings | 6,309 |
| Tristel | 267 |
| Diaceutics | 213 |
| Animalcare Group | 201 |
Transgene News
- 3 months ago - Transgene SA (TRGNF) Discusses TG4050 Phase I Immunological Data in Head and Neck Cancer from SITC Presentation Transcript - Seeking Alpha
- 5 months ago - Transgene SA (FRA:TGNA) (Half Year 2025) Earnings Call Highlights: Strategic Focus on TG4050 ... - GuruFocus
- 5 months ago - Half Year 2025 Transgene SA Earnings Call Transcript - GuruFocus
- 5 months ago - Transgene SA 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 5 months ago - Transgene SA (TRGNF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 years ago - Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript - Seeking Alpha
- 3 years ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire
- 3 years ago - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration - Business Wire